Numotion Ally Podcast Launches for Catheter Users
The first episode of the Numotion Ally podcast for the provider’s catheter customers is live.
Episode 1’s topic — “Questions You’re Too Afraid to Ask” — covered topics from “bathroom fails to TSA [Transportation Security Administration] stories to the worst catheter advice ever.” (Hint: Always wash your hands, even when using closed catheter systems designed to reduce the risk of urinary tract infections.)
Numotion catheter customers, as well as clinicians, can register for free to access Ally’s resources, including the new podcast.
Lifeward Receives CE Mark Approval for ReWalk 7 Personal Exoskeleton
Lifeward Ltd. (Nasdaq: LFWD) has received CE mark approval for its ReWalk 7 personal exoskeleton, thus opening the door to commercial sales in Europe.
The seventh generation of ReWalk features cloud connectivity, push-button control, customizable walking speeds, and “seamless activation of stairs and curbs,” Lifeward said in a Sept. 8 announcement.
Lifeward — based in Marlborough, Massachusetts, and Yokneam Illit, Israel — said European customers currently represent about 40% of the company’s exoskeleton sales, with most of those sales generated in Germany.
“The ReWalk 7 represents a major advancement in personal exoskeleton technology, designed to deliver superior control, engagement, and real-world mobility for individuals with spinal cord injury,” said Mark Grant, CEO of Lifeward. “Achieving CE mark approval is a pivotal regulatory milestone for Lifeward. With reimbursement already broadly established in Germany, this foundation positions us to drive meaningful near-term commercial adoption and revenue growth in Europe, while also providing a proven model we are beginning to replicate in other strategic markets, including the United States.”
Lifeward began selling the ReWalk 7 in the United States in April.
